NCT07339059 2026-04-09Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerHenry Ford Health SystemPhase 2 Recruiting35 enrolled